[Omail-admin-devel] The Quest is On for a Remedy for Pancreatic Cancer

[Today in t. m. <vi...@pe...>]

The Quest is On for a Cure for Pancreatic Cancer

Recent clinical trials are uncovering hopeful results in Pancreatic Cancer,
the 4th prominent cause of cancer death in the U.S.A. that kills more than
38,000 residents of the US a year with 75 percent of those diagnosed with
pancreatic cancer dying within one year.

As Nuvilex (NVLX) arranges for large-scale Phase 3 clinical trials of its
remedy for established pancreatic cancer, it appears that the company could
conceivably see a large swell in share price, related to the route that
Pharmasset, Inc. took as it progressed PSI-7977 for hepatitis C.  Shares of
(then) VRUS went on a mammoth climb from around $4 per share in 2007 to
attain approximately $160 per share about 3 years later. After stock
splits, when all was said a done, early shareholders took in earnings in
the area of 6,800%!  All this for fundamentally one medication that was in
Phase 2 trials!

Read what the authorities are saying about Nuvilex, Inc. ‘s potential!
http://perectdiscoveraccount.com/link.php?M=32404335&N=716&L=16&F=T


The usage of research materials created by the author is done at your own
risk.  You are incited to do your own research and due diligence before
making any investment decision in regards to the secu rity discussed
herein. The author has not been compensated by any entity in connection
with the distribution of these materials. You should presume that as of the
date of this report or letter, the author, (possibly along with or through
our owners, affiliates, employees and/or consultants”) (communally
referred to as the author) has a position in all company shares (and/or
options of the shares) covered herein that is consistent with the position
set forth in our report. In connection with NVLX, the author has taken a
long position. Following the distribution of any report or letter, the
author plans to continue engaging in trnsactns in the secu rity covered
herein, and we may be long, short, and/or neutral at any time hereafter
regardless of our initial position and we preserve the right to procure or
trade all or part of our position at any time without notice.  This
practice could end in our trading securities at any time before, during,
and/or after the distribution of this report. Full disclaimer:
http://perectdiscoveraccount.com/link.php?M=32404335&N=716&L=8&F=T

Unsub:http://perectdiscoveraccount.com/unsubscribe.php?M=32404335&C=5d4b8fd1f56cf2afa75e78fadbfe2a99&L=77&N=716

795 Folsom ST, 1st Floor, San Francisco, Ca 94107  United States